Why Doxycycline Replaced Azithromycin for Chlamydia in 2021

For more than two decades, a single 1-gram dose of azithromycin was the default treatment for chlamydia. It was simple, it could be swallowed in front of the clinician, and it worked well for most genital infections. In July 2021, the U.S. Centers for Disease Control and Prevention (CDC) changed course. It named a seven-day course of doxycycline as the preferred treatment for most adolescents and adults, and moved azithromycin to the list of alternatives. This article explains why. The short version is that randomized trials and pooled analyses showed doxycycline cures chlamydia in the rectum far more reliably than single-dose azithromycin. They also showed a smaller but consistent advantage for genital infection. The article also covers the situations in which single-dose azithromycin remains a sound, guideline-supported choice, most importantly during pregnancy.

What the 2021 guidelines actually recommend

The CDC's Sexually Transmitted Infections Treatment Guidelines, 2021 were published in the agency's Morbidity and Mortality Weekly Report. For chlamydia in non-pregnant adolescents and adults, they list:

• Recommended: doxycycline 100 mg by mouth twice daily for 7 days.
• Alternatives: azithromycin 1 g by mouth as a single dose, or levofloxacin 500 mg by mouth once daily for 7 days.
• In pregnancy: azithromycin 1 g as a single dose is recommended, with amoxicillin 500 mg three times daily for 7 days as an alternative.

Azithromycin was not declared ineffective, and it was not removed from the guidelines. The change reflects a judgment that doxycycline is the more dependable drug when both are reasonable options.

The rectal cure-rate evidence

The decisive evidence concerned infection of the rectum. Rectal chlamydia is far more common than many people assume. It occurs in men who have sex with men. It also occurs in women, including many who report no anal sex. Studies that tested women at several anatomical sites have repeatedly found rectal chlamydia in a large share of those with genital infection. The likely route is spread of the organism from the genital tract. Because routine testing usually samples only the genital site, these rectal infections often go undetected. Whatever drug is chosen therefore needs to clear them as well.

The research developed in stages:

• Pooled observational data (2015). Researchers led by Fabian Kong at the University of Melbourne published a systematic review and meta-analysis in the Journal of Antimicrobial Chemotherapy. Across the available studies, the pooled cure rate for rectal chlamydia was roughly 83% with azithromycin and over 99% with doxycycline. The studies were observational rather than randomized, so the finding was strongly suggestive but not conclusive.
• A U.S. randomized trial (2021). Julia Dombrowski and colleagues at the University of Washington in Seattle randomized men who have sex with men with rectal chlamydia to one of the two drugs. They reported the results in Clinical Infectious Diseases. Doxycycline cured essentially every infection. Azithromycin cured roughly three in four. The trial was relatively small, but the gap was large.
• A larger Australian randomized trial (2021). A double-blind trial led by Andrew Lau and colleagues, with the Melbourne Sexual Health Centre group, was published in the New England Journal of Medicine. It enrolled several hundred men with asymptomatic rectal chlamydia. Microbiologic cure was about 97% with doxycycline and about 76% with azithromycin, a difference of roughly 20 percentage points.
• Evidence in women. In the Netherlands, the FemCure study was a prospective cohort rather than a randomized trial. It followed women with rectal chlamydia treated with each drug and found substantially higher rectal cure with doxycycline. Randomized data in women remain more limited than in men. Still, the direction of the evidence is consistent across populations.

Taken together, this body of evidence is strong. Two independent randomized trials in different countries, plus observational data in women, all pointed the same way, and the size of the difference was clinically meaningful. One in four rectal infections persisting after treatment matters both for the patient and for anyone the patient later has sex with.

Why azithromycin underperforms in the rectum is less settled. Proposed explanations include differences in how the drug reaches rectal tissue, higher bacterial loads at that site, and the different way the two drugs are taken: one dose versus a sustained week-long exposure. True antibiotic resistance in Chlamydia trachomatis does not appear to be a major factor. These mechanisms remain hypotheses rather than established facts.

What about genital infection?

For infection of the cervix or urethra, both drugs work well, and the gap between them is narrower. A 2014 meta-analysis of randomized trials by the same Melbourne group, published in Clinical Infectious Diseases, found doxycycline modestly more effective, by a few percentage points. The difference appeared larger in men with symptomatic urethral infection.

A carefully controlled randomized trial led by William Geisler at the University of Alabama at Birmingham was published in the New England Journal of Medicine in 2015. It studied adolescents and young adults in juvenile correctional facilities, where every dose could be directly observed. Cure rates were about 97% with azithromycin and 100% with doxycycline. Azithromycin performed very well. However, the trial could not confirm that it was statistically "non-inferior" to doxycycline by the margin the investigators had set.

A modest genital advantage, combined with a large rectal advantage and the frequency of unrecognized rectal infection, led the CDC to prefer doxycycline as the default.

When single-dose azithromycin remains appropriate

Azithromycin's great strength has always been practical. One dose, taken on the spot, removes any question of whether the patient will finish a week of twice-daily pills. That still matters in several situations:

• Pregnancy. The CDC advises against doxycycline in the second and third trimesters because of concerns about effects on the developing child's teeth and bones. Azithromycin is the recommended treatment in pregnancy, and amoxicillin is the alternative.
• Doubts about completing a seven-day course. Some patients have unstable housing, chaotic schedules, or a history of not finishing medications. For them, a directly observed single dose may cure more infections in practice than a theoretically better regimen that is abandoned on day three.
• Intolerance or allergy to tetracyclines. This includes people who cannot tolerate doxycycline's side effects.
• Clinical judgment about a specific patient. Examples include drug interactions or other individual circumstances that a physician weighs with the patient.

Doxycycline also has practical drawbacks. It can cause nausea and increased sensitivity to sunlight. It can irritate the esophagus if swallowed without enough water or taken just before lying down. These are usually manageable, but patients should know about them before starting.

A pregnancy diagnosis does not change the goal of treatment. It adds a second patient whose life deserves the same care. Untreated chlamydia can be passed to the baby during delivery and has been linked to eye infection and pneumonia in newborns. Untreated infection has also been associated with adverse pregnancy outcomes. For this reason, the CDC recommends a test of cure about four weeks after treatment in pregnancy, retesting within three months, and screening early in pregnancy for those at risk. These steps protect both mother and child.

Stewardship beyond the prescription

Both drugs come, ultimately, from the soil. Doxycycline is a semi-synthetic member of the tetracycline family, first discovered in Streptomyces bacteria living in soil. Azithromycin was developed in Croatia around 1980 as a modification of erythromycin, which was isolated in the early 1950s from a soil organism collected in the Philippines. Remedies of this kind lay hidden in ordinary earth for most of human history. That is a reasonable occasion for gratitude, and also for the responsibility to use these medicines well rather than carelessly.

Using them well means more than picking the right pill:

• Finish the course. Doxycycline's advantage depends on all 14 doses being taken.
• Abstain until treatment is complete. The CDC advises avoiding sex until seven days after a single azithromycin dose, or until a seven-day course is finished, and until partners have been treated.
• Make sure partners are treated. Otherwise reinfection is likely. Some states permit clinicians to provide medication for a partner directly. The rules vary by state.
• Retest at about three months. Reinfection is common, and repeat infections in women raise the risk of pelvic inflammatory disease, tubal scarring, ectopic pregnancy, and infertility.

Protecting future fertility is a serious matter. Chlamydia often causes no symptoms while it quietly damages the reproductive tract. Careful treatment and follow-up are a way of safeguarding a person's ability to build a family later. The most reliable protection against reinfection remains a mutually faithful relationship with an uninfected partner.

Making the decision with your physician

Guidelines describe what works best for most people. They do not replace a conversation between a patient and a physician who knows that patient's circumstances. A well-informed patient can reasonably ask:

• Which sites were tested?
• Could I have an infection at a site that was not tested?
• Is there any reason I should not take doxycycline?
• Am I, or might I be, pregnant?
• Will I realistically complete a week of twice-daily tablets?

The answers shape which regimen makes the most sense. The evidence favoring doxycycline is sound. So is the case for azithromycin when pregnancy, adherence, or intolerance is in play. Knowing the reasons behind each lets patients take part in the choice rather than simply receive it.

Key takeaway: Doxycycline became the preferred chlamydia treatment in 2021 mainly because randomized trials showed it cures rectal infection far more reliably than single-dose azithromycin, but azithromycin remains the recommended choice in pregnancy and a reasonable option when a seven-day course is impractical or not tolerated.